Robert E. Davis, SVP, Chief Scientific Officer at Intra-Cellular Therapies, Inc. (ITCI), sold 1,115 shares at $15.60 ($17K) on 2018-01-04, disclosed to the SEC on 2018-01-05.
Scheduled sale ($17k) by SVP, Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| ITCI | SELL | 2018-12-07 | $12K | — | Filing → |
| ITCI | SELL | 2017-12-06 | $10K | — | Filing → |